These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 17275980)

  • 21. Botulinum toxin in the treatment of OAB, BPH, and IC.
    Smith CP
    Toxicon; 2009 Oct; 54(5):639-46. PubMed ID: 19268490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Satisfaction with urethral injection of botulinum toxin A for detrusor sphincter dyssynergia in patients with spinal cord lesion.
    Kuo HC
    Neurourol Urodyn; 2008; 27(8):793-6. PubMed ID: 18508331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature.
    Moore DC; Cohn JA; Dmochowski RR
    Toxins (Basel); 2016 Mar; 8(4):88. PubMed ID: 27023601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Botulinum toxin--new mechanisms, new therapeutic directions?
    Chapple C; Patel A
    Eur Urol; 2006 Apr; 49(4):606-8. PubMed ID: 16457945
    [No Abstract]   [Full Text] [Related]  

  • 25. Editorial comment on: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
    Schurch B
    Eur Urol; 2009 Mar; 55(3):711-2. PubMed ID: 18814956
    [No Abstract]   [Full Text] [Related]  

  • 26. Editorial comment on: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
    Fowler CJ
    Eur Urol; 2009 Mar; 55(3):712. PubMed ID: 18814958
    [No Abstract]   [Full Text] [Related]  

  • 27. Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application.
    Giannantoni A; Mearini E; Del Zingaro M; Santaniello F; Porena M
    BJU Int; 2008 Jul; 102 Suppl 1():2-6. PubMed ID: 18665971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Botulinum toxin in urology: evaluation using an evidence-based medicine approach.
    Smith CP; Somogyi GT; Boone TB
    Nat Clin Pract Urol; 2004 Nov; 1(1):31-7. PubMed ID: 16474464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
    Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
    J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial.
    Sahai A; Khan MS; Dasgupta P
    J Urol; 2007 Jun; 177(6):2231-6. PubMed ID: 17509328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction.
    Akbar M; Abel R; Seyler TM; Bedke J; Haferkamp A; Gerner HJ; Möhring K
    BJU Int; 2007 Sep; 100(3):639-45. PubMed ID: 17532858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Editorial comment on: neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre.
    Wyndaele JJ
    Eur Urol; 2008 May; 53(5):1019-20. PubMed ID: 17950988
    [No Abstract]   [Full Text] [Related]  

  • 33. [Detrusor-sphincter dyssynergia and botulinum toxin].
    Parratte B; Bonniaud V; Tatu L; Metton G; Michel F; Cosson A; Monnier G
    Ann Readapt Med Phys; 2003 Jul; 46(6):319-25. PubMed ID: 12928137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.
    Apostolidis A; Jacques TS; Freeman A; Kalsi V; Popat R; Gonzales G; Datta SN; Ghazi-Noori S; Elneil S; Dasgupta P; Fowler CJ
    Eur Urol; 2008 Jun; 53(6):1245-53. PubMed ID: 18343564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Injection of botulinum toxin type A in the urethral sphincter to treat lower urinary tract dysfunction: a review of indications, techniques and results.
    Karsenty G; Baazeem A; Elzayat E; Corcos J
    Can J Urol; 2006 Apr; 13(2):3027-33. PubMed ID: 16672114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity].
    Chenet A; Perrouin-Verbe B; Le Normand L; Labat JJ; Brunel P; Lefort M; Mathé JF
    Ann Readapt Med Phys; 2007 Nov; 50(8):651-60. PubMed ID: 17490775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravesical injection of botulinum toxin for the treatment of overactive bladder.
    Ho MH; Lin LL; Haessler AL; Bhatia NN
    Curr Opin Obstet Gynecol; 2005 Oct; 17(5):512-8. PubMed ID: 16141766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intradetrusor botulinum toxin injections for neurogenic overactive bladder: are we there yet?
    Lemack GE
    Eur Urol; 2008 Feb; 53(2):240-1. PubMed ID: 17997019
    [No Abstract]   [Full Text] [Related]  

  • 39. Botulinum toxin injection therapy in the management of lower urinary tract dysfunction.
    Patel AK; Chapple CR
    Int J Clin Pract Suppl; 2006 Dec; (151):1-7. PubMed ID: 17169004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation.
    Lucioni A; Bales GT; Lotan TL; McGehee DS; Cook SP; Rapp DE
    BJU Int; 2008 Feb; 101(3):366-70. PubMed ID: 18184328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.